front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |review

Fig. 1. Schematic representation of AACs and aminoglycosides used in this study. All AACs were prepared as acetate salts. (A) NeoR6,hexa-arginine�neomycin conjugate; NeoR1, a 1:1 mixture of two mono-arginine�neomycin conjugates; NeoR2, a di-arginine�neomycin conjugate; NeamR1, a mono-arginine�neamine conjugate; NeamR4, a tetra-arginine�neamine conjugate; ParomR1, a mono-arginine�paromomycin conjugate; and ParomR5, a penta-arginine�paromomycin conjugate. (B) R3G, a tri-arginine�gentamycin C1 conjugate.